You are here
ARLINGTON HEIGHTS, Ill. February 15, 2012 - The American College of Allergy, Asthma and Immunology (ACAAI) recognizes Teva Respiratory for its continued leadership and support of important educational issues related to respiratory health, particularly under diagnosed and poorly managed asthma and exercise-induced bronchoconstriction. ACAAI announced today that they will partner again this year with Teva Respiratory to bring free asthma screenings to communities nationwide.
Almost 130,000 people have been screened since the start of the Nationwide Asthma Screening Program, with half of those screened referred for a diagnosis. Continued financial support by Teva Respiratory provides the funding for the public education materials, publicity and resources needed to conduct screenings. On a local level, Teva representatives help at three out of every four screenings.
We are thrilled to once again partner with Teva, said allergist John Winder, M.D. chair of the ACAAI Nationwide Asthma Screening Program. This program would not be possible without their continued support.
More than 24 million Americans, including 7.1 million children, have asthma. The disease is responsible for almost 4,000 deaths a year. An asthma attack is often triggered by allergens such as pollen, dust and animal dander, certain drugs and food additives or respiratory infections. Although the exact cause of asthma is unknown, many treatments are available to control this chronic inflammation of the airways in the lungs.
About Teva Respiratory
Teva Respiratory is the U.S.-based respiratory subsidiary of Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA). Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing accessible generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,300 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on neurological, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 46,000 people around the world and reached $16.1 billion in net sales in 2010.